Covid-19 roundup: Alex­ion's C5 in­hibitor Ul­tomiris miss­es the PhI­II bar; Lon­za in wait­ing game to use in­gre­di­ents in Mod­er­na vac­cine

C5 in­hi­bi­tion isn’t the an­swer to the search for treat­ments for se­vere Covid-19 af­ter all.

Alex­ion is paus­ing en­roll­ment to a Phase III study test­ing Ul­tomiris, the long-act­ing fol­low-on to Soliris, among pa­tients re­quir­ing me­chan­i­cal ven­ti­la­tion af­ter the in­de­pen­dent da­ta mon­i­tor­ing com­mit­tee raised a lack of ef­fi­ca­cy in an in­ter­im analy­sis. Among 122 pa­tients (out of a planned en­roll­ment of 270), there was no mean­ing­ful dif­fer­ence in sur­vival at Day 29.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER